BTAI - BioXcel Therapeutics Inc
1.48
-0.130 -8.784%
Share volume: 2,900,127
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$1.61
-0.13
-0.08%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-09-2024 | 08-06-2024 | 11-14-2024 | 03-28-2025 | 05-12-2025 | 08-12-2025 | 11-12-2025 | |
| Total revenue | 582.000 K | 1.104 M | 214.000 K | 366.000 K | 168.000 K | 120.000 K | 98.000 K | |
| Cost of revenue | 80.000 K | 62.000 K | 1.170 M | 831.000 K | 14.000 K | 107.000 K | 11.000 K | |
| Gross profit | 502.000 K | 1.042 M | -956.000 K | -465.000 K | 154.000 K | 13.000 K | 87.000 K | |
| 107.57% | -191.75% | 51.36% | 133.12% | -91.56% | 569.23% | |||
| Operating expenses | 24.665 M | 17.482 M | 12.784 M | 9.996 M | 10.253 M | 15.865 M | 14.121 M | |
| Selling general and admin | 13.264 M | 9.450 M | 7.683 M | 4.095 M | 5.699 M | 5.609 M | 5.381 M | |
| Research and development | 11.401 M | 8.032 M | 5.101 M | 5.901 M | 4.554 M | 10.256 M | 8.740 M | |
| Total expenses | 24.665 M | 18.338 M | 14.337 M | 10.028 M | 10.253 M | 15.865 M | 14.315 M | |
| -25.65% | -21.82% | -30.06% | 2.24% | 54.74% | -9.77% | |||
| Operating income | -24.163 M | -17.296 M | -15.293 M | -10.493 M | -10.099 M | -15.852 M | -14.228 M | |
| Ebit | -24.131 M | -5.270 M | -10.476 M | -7.195 M | -3.540 M | -15.195 M | -26.774 M | |
| Pretax income | -26.791 M | -8.299 M | -13.650 M | -10.859 M | -7.254 M | -19.187 M | -30.911 M | |
| -69.02% | 64.48% | -20.45% | -33.20% | 164.50% | 61.10% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -26.791 M | -8.299 M | -13.650 M | -10.859 M | -7.254 M | -19.187 M | -30.911 M | |
| 69.02% | -64.48% | 20.45% | 33.20% | -164.50% | -61.10% |